Literature DB >> 11422182

Psoriasis--epidemiology and clinical spectrum.

E Christophers1.   

Abstract

Despite psoriasis being a common skin disease, there are still a number of unanswered questions. One of these is the prevalence of the disease, as there is a lack of specific data, with the majority of studies reporting estimates only. Population based studies are rare and longitudinal observations on changing prevalence rates are lacking. This contrasts with other T-cell mediated autoimmune diseases where the number of those affected is rising. Epidemiological studies revealed that a distinct group of diseases is quite frequently associated with psoriasis, e.g. arthritis, colitis, diabetes and hypertension. In contrast, atopic dermatitis and allergies are less frequently seen compared to normal rates of occurrence. As the psoriatic immune response pattern relates to activated Th-1 cells, psoriasis and atopic dermatitis appear to be mutually exclusive due to the Th-1/Th-2 dichotomy.

Entities:  

Mesh:

Year:  2001        PMID: 11422182     DOI: 10.1046/j.1365-2230.2001.00832.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  164 in total

Review 1.  New insights in the immunologic basis of psoriasis.

Authors:  Kristine E Nograles; Batya Davidovici; James G Krueger
Journal:  Semin Cutan Med Surg       Date:  2010-03

2.  Psoriasis is associated with a greater risk of incident venous thromboembolism: the Iowa Women's Health Study.

Authors:  P L Lutsey; A E Prizment; A R Folsom
Journal:  J Thromb Haemost       Date:  2012-04       Impact factor: 5.824

Review 3.  Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring.

Authors:  Raja K Sivamani; Heidi Goodarzi; Miki Shirakawa Garcia; Siba P Raychaudhuri; Lisa N Wehrli; Yoko Ono; Emanual Maverakis
Journal:  Clin Rev Allergy Immunol       Date:  2013-04       Impact factor: 8.667

Review 4.  Immunopathogenesis of psoriasis.

Authors:  Brian J Nickoloff; Jian-Zhong Qin; Frank O Nestle
Journal:  Clin Rev Allergy Immunol       Date:  2007-10       Impact factor: 8.667

Review 5.  Early Recognition and Treatment Heralds Optimal Outcomes: the Benefits of Combined Rheumatology-Dermatology Clinics and Integrative Care of Psoriasis and Psoriatic Arthritis Patients.

Authors:  Teo Soleymani; Soumya M Reddy; Jeffrey M Cohen; Andrea L Neimann
Journal:  Curr Rheumatol Rep       Date:  2017-11-20       Impact factor: 4.592

6.  Pustular psoriasis complicated with acute generalized exanthematous pustulosis.

Authors:  Mariam Abbas; Karen Holfeld; Danielle Desjardins; June Zimmer
Journal:  J Dermatol Case Rep       Date:  2014-06-30

7.  Isoliquiritigenin prevents the progression of psoriasis-like symptoms by inhibiting NF-κB and proinflammatory cytokines.

Authors:  Yangping Wu; Xiangzheng Chen; Xiaojun Ge; Hongwei Xia; Yuxi Wang; Siyuan Su; Wenting Li; Tinghan Yang; Mingtian Wei; Hang Zhang; Lantu Gou; Jiong Li; Xian Jiang; Jinliang Yang
Journal:  J Mol Med (Berl)       Date:  2015-09-18       Impact factor: 4.599

8.  Hodgkin's lymphoma in a patient on adalimumab treatment for psoriasis.

Authors:  Nouf Alballa; Alanoud Alyousef; Albatool Alamari; Ahmed Abdullah Alhumidi; Mohammed Ayesh Zayed; Leena Zeitouni; Fahad Mohammed Alsaif
Journal:  AME Case Rep       Date:  2018-12-24

9.  Consumption of polyunsaturated fatty acids and risk of incident psoriasis and psoriatic arthritis from the Nurses' Health Study II.

Authors:  M K Park; W Li; S Y Paek; X Li; S Wu; T Li; A A Qureshi; E Cho
Journal:  Br J Dermatol       Date:  2017-06-05       Impact factor: 9.302

10.  Efalizumab-induced severe thrombocytopenia can be resolved.

Authors:  Francesca Prignano; F Zanieri; S Mokhtarzadeh; T Lotti
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.